Prevention and management of cardiotoxicity from antineoplastic therapy

Asher A Chanan Khan, Sridhar Srinivasan, Myron S. Czuczman

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalJournal of Supportive Oncology
Volume2
Issue number3
StatePublished - May 2004
Externally publishedYes

Fingerprint

Antineoplastic Agents
Appointments and Schedules
Preexisting Condition Coverage
Anthracyclines
Biological Factors
Heart Diseases
Therapeutics
Pharmaceutical Preparations
Cardiotoxicity
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevention and management of cardiotoxicity from antineoplastic therapy. / Chanan Khan, Asher A; Srinivasan, Sridhar; Czuczman, Myron S.

In: Journal of Supportive Oncology, Vol. 2, No. 3, 05.2004, p. 251-256.

Research output: Contribution to journalArticle

Chanan Khan, Asher A ; Srinivasan, Sridhar ; Czuczman, Myron S. / Prevention and management of cardiotoxicity from antineoplastic therapy. In: Journal of Supportive Oncology. 2004 ; Vol. 2, No. 3. pp. 251-256.
@article{7f2753e3c6bf4919a57c896d6b8a6654,
title = "Prevention and management of cardiotoxicity from antineoplastic therapy",
abstract = "Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.",
author = "{Chanan Khan}, {Asher A} and Sridhar Srinivasan and Czuczman, {Myron S.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "2",
pages = "251--256",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "3",

}

TY - JOUR

T1 - Prevention and management of cardiotoxicity from antineoplastic therapy

AU - Chanan Khan, Asher A

AU - Srinivasan, Sridhar

AU - Czuczman, Myron S.

PY - 2004/5

Y1 - 2004/5

N2 - Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.

AB - Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines. Recently, some of the newer drugs and biologic agents that have been introduced into cancer therapeutics also have been shown to have potential cardiotoxic effects. The spectrum of cardiac side effects varies with the antineoplastic agent, dose, and schedule used. Important risk factors associated with cardiotoxicity are cumulative dose, infusion schedule, and pre-existing cardiac disease. This review focuses on the various adverse cardiovascular events associated with antineoplastic agents, what to anticipate, how to recognize the toxicity, how to prevent and minimize the cardiac side effects, and how to manage the full-blown toxicity if and when it occurs.

UR - http://www.scopus.com/inward/record.url?scp=4644362894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644362894&partnerID=8YFLogxK

M3 - Article

C2 - 15328825

AN - SCOPUS:4644362894

VL - 2

SP - 251

EP - 256

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 3

ER -